Grifols SA

Grifols, S.A. researches, develops, produces, and markets plasma-derived medicines globally, including in the United States, Canada, Spain, and Europe. The company operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. Grifols offers various hemoderivatives from human plasma for treating immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology. It also markets diagnostic testing equipment, reagents, and other equipment, alongside providing transfusion medicine, clinical diagnostics, and testing services. The company supplies biological products such as albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharmaceutical and biotech companies for biopharma applications. It also provides whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. Grifols offers healthcare solutions for hospitals, including intravenous solutions, high-tech solutions for automating hospital processes, clinical nutrition, and medical devices for services like interventional neuroradiology, hemodynamics, urology, anesthesiology, and cardiovascular surgery. Additionally, it provides manufacturing services to third parties and conducts research activities. The company's operations also encompass engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization; travel agency services; reinsurance; support services; law business; and consultation, administration, and financing services. Grifols, S.A. was founded in 1909 and is headquartered in Barcelona, Spain.